Yubo International Biotech Limited (YBGJ)
USD 0.08
(56.51%)
USD 0.08
(56.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 1.25 Million USD | -46.78% |
| 2021 | 2.36 Million USD | 21.12% |
| 2020 | 1.95 Million USD | 4165.4% |
| 2019 | -48 Thousand USD | 17.24% |
| 2018 | -58 Thousand USD | -138.93% |
| 2017 | 149 Thousand USD | 136.51% |
| 2016 | 63 Thousand USD | 208.62% |
| 2015 | -58 Thousand USD | 49.57% |
| 2014 | -115 Thousand USD | 8.0% |
| 2013 | -125 Thousand USD | -165.96% |
| 2012 | -47 Thousand USD | 41.25% |
| 2011 | -80 Thousand USD | -26.98% |
| 2010 | -63 Thousand USD | 50.78% |
| 2009 | -128 Thousand USD | -80.28% |
| 2008 | -71 Thousand USD | 37.17% |
| 2007 | -113 Thousand USD | -25.56% |
| 2006 | -90 Thousand USD | 99.91% |
| 2005 | -101 Million USD | -47995.24% |
| 2004 | -210 Thousand USD | 93.1% |
| 2003 | -3.04 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 382.22 Thousand USD | 612.73% |
| 2023 Q2 | 368.16 Thousand USD | -3.68% |
| 2022 Q4 | -74.54 Thousand USD | -130.08% |
| 2022 Q3 | 247.87 Thousand USD | -50.16% |
| 2022 FY | 1.25 Million USD | -46.78% |
| 2022 Q1 | 587.2 Thousand USD | -3.27% |
| 2022 Q2 | 497.35 Thousand USD | -15.3% |
| 2021 Q1 | 754.16 Thousand USD | -30.8% |
| 2021 Q2 | 583.08 Thousand USD | -22.68% |
| 2021 Q3 | 419.21 Thousand USD | -28.11% |
| 2021 Q4 | 607.05 Thousand USD | 44.81% |
| 2021 FY | 2.36 Million USD | 21.12% |
| 2020 Q4 | 1.08 Million USD | 150.0% |
| 2020 FY | 1.95 Million USD | 4165.4% |
| 2020 Q3 | 435.93 Thousand USD | 52.69% |
| 2020 Q2 | 285.5 Thousand USD | 102.63% |
| 2020 Q1 | 140.9 Thousand USD | 1661.28% |
| 2019 FY | -48 Thousand USD | 17.24% |
| 2019 Q4 | 8000.00 USD | 0.0% |
| 2019 Q1 | 8000.00 USD | 14.29% |
| 2019 Q2 | - USD | -100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | 7000.00 USD | -41.67% |
| 2018 FY | -58 Thousand USD | -138.93% |
| 2018 Q3 | 12 Thousand USD | 0.0% |
| 2018 Q1 | -8000.00 USD | -136.36% |
| 2018 Q2 | - USD | 100.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q3 | 22 Thousand USD | 0.0% |
| 2017 FY | 149 Thousand USD | 136.51% |
| 2017 Q1 | 96 Thousand USD | 0.0% |
| 2017 Q4 | 22 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | 13 Thousand USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | 63 Thousand USD | 208.62% |
| 2015 Q1 | 11 Thousand USD | -35.29% |
| 2015 FY | -58 Thousand USD | 49.57% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | 14 Thousand USD | 0.0% |
| 2014 FY | -115 Thousand USD | 8.0% |
| 2014 Q4 | 17 Thousand USD | 21.43% |
| 2014 Q3 | 14 Thousand USD | 0.0% |
| 2013 Q1 | 14 Thousand USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | -125 Thousand USD | -165.96% |
| 2012 FY | -47 Thousand USD | 41.25% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | 9000.00 USD | -30.77% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | -80 Thousand USD | -26.98% |
| 2011 Q1 | 11 Thousand USD | -15.38% |
| 2011 Q4 | 13 Thousand USD | 0.0% |
| 2010 Q4 | 13 Thousand USD | -66.67% |
| 2010 Q1 | 20 Thousand USD | 42.86% |
| 2010 FY | -63 Thousand USD | 50.78% |
| 2010 Q3 | 39 Thousand USD | 0.0% |
| 2009 Q1 | 10 Thousand USD | 0.0% |
| 2009 Q4 | 14 Thousand USD | 0.0% |
| 2009 FY | -128 Thousand USD | -80.28% |
| 2008 FY | -71 Thousand USD | 37.17% |
| 2008 Q1 | -79 Thousand USD | 0.0% |
| 2007 Q1 | 4000.00 USD | 0.0% |
| 2007 FY | -113 Thousand USD | -25.56% |
| 2006 Q1 | -65 Thousand USD | 0.0% |
| 2006 FY | -90 Thousand USD | 99.91% |
| 2005 Q1 | 101.86 Million USD | 0.0% |
| 2005 FY | -101 Million USD | -47995.24% |
| 2004 FY | -210 Thousand USD | 93.1% |
| 2004 Q1 | -127 Thousand USD | 0.0% |
| 2003 FY | -3.04 Million USD | 0.0% |
| 2003 Q1 | 58 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | 56.069% |
| Ansell Limited | 495.5 Million USD | 99.746% |
| Ansell Limited | 495.5 Million USD | 99.746% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | 98.481% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | 27.322% |
| Psykey, Inc. | 1.21 Million USD | -3.658% |
| ConvaTec Group Plc | 910.31 Million USD | 99.862% |
| ConvaTec Group Plc | 872.5 Million USD | 99.856% |
| Encision Inc. | 3.77 Million USD | 66.694% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -787.008% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -1044.24% |
| Innovative MedTech Inc. | 6.09 Million USD | 79.376% |
| LifePoint, Inc. | 7.42 Million USD | 83.056% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | 80.188% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | -47.12% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 726.13 Thousand USD | -73.229% |
| Reflect Scientific, Inc. | 1.06 Million USD | -18.255% |
| SmileDirectClub, Inc. | 517 Million USD | 99.757% |
| Sector 10, Inc. | 39.84 Thousand USD | -3057.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 99.981% |
| SheerVision, Inc. | 2.33 Million USD | 46.052% |
| United Health Products, Inc. | 2.42 Million USD | 48.162% |
| Vasamed, Inc. | 4.67 Million USD | 73.082% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | 50.899% |